FDA approves Biogen's MS drug Plegridy

Biogen Idec says that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.

The company said Friday that the Food and Drug Administration cleared the , dubbed Plegridy, after reviewing results from a study that involved more than 1,500 people with the disease.

Multiple sclerosis is a disease of the immune system in which the body attacks the brain and .

Its symptoms can come and go, often reappearing months later.

The European Commission recently approved Plegridy.

Biogen also markets the drugs Avonex and Tysabri.

Shares of Biogen Idec Inc. ended regular trading up $5.46, or 1.6 percent, to $342.47 on Friday.

The stock is up 22 percent this year.

Related Stories

US approves new multiple sclerosis capsules

date Mar 27, 2013

The U.S. Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease.

FDA clears safety test to screen Tysabri patients

date Jan 20, 2012

(AP) -- The Food and Drug Administration on Friday approved a new diagnostic test to help identify patients who have an increased risk of developing a rare brain infection while taking Biogen Idec's multiple sclerosis drug ...

Leukoencephalopathy risk factors ID'd for MS drug

date May 17, 2012

(HealthDay) -- Drug company researchers say they've determined which multiple sclerosis patients are most vulnerable to developing a rare brain infection while taking a powerful drug called Tysabri (natalizumab).

Novartis gains FDA approval for new MS drug

date Sep 22, 2010

(AP) -- Federal health regulators have approved the first pill to treat the underlying causes of multiple sclerosis, a debilitating nervous system disorder that has traditionally been treated with injectable drugs.

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

date May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.